the UAE-based Mubadala Company announced that it has entered into a strategic partner in the German company (Evoteq S / E), which specializes in the field of drug discovery and advanced treatment regimens.
According to the Emirates News Agency, Evoteq (registered on the Frankfurt Stock Exchange under the symbol EVT, MDAX / TecDAX /), announced that it will issue 11,478,298 new shares for Mubadala Investment and Novo Holdings A / This brings Evoteq's total cash reserves to the equivalent of 250 million euros.
Under this private placement in the capital increase, Mubadala, which has strategic investments in the healthcare sector, will invest € 200 million in exchange for the acquisition of shares in Evoteq. On the basis of 21.7802 euros per share, equivalent to about 5.6% of the remaining shares. Novo Holdings A / S, a current shareholder of Evoteq, will also invest € 50 million to support Evoteq's ambitious growth program and raise its shareholding in the company to about 10.9% of the total remaining shares.
Evoteq has succeeded in developing a unique strategy that qualifies it to become a world leader in the development of innovative and integrated treatment regimens that are the best and the first of their kind, which will produce a long series of Joint new products.
Evoteq has significantly expanded its operations worldwide and currently employs more than 3,400 employees in 14 locations around the world, including Germany, the United States, France, Italy and the United Kingdom. And Austria.
Evoteq seeks to take advantage of its proprietary technologies and its wide network of distinguished partnerships, in order to improve access to many effective and effective drugs and make them available to consumers around the world. Future investments will be used to support Evoteq's strategy and help it implement the next phase of strategic growth, which includes: implementing the strategy to strengthen the global infrastructure for biological medicines, investing in biomedical prediction techniques, as well as investments in new cell and gene therapies in diabetes, rare diseases and tumors. .
The stages of strategic growth also include: Investing in facilitating access to patient data to develop advanced treatments for kidney, liver, tumors, heart, gynecology and other diseases in addition to developing stem cell therapy programs And machine learning, enhancing the company's presence in all of its current locations in the United States and Europe, and taking faster steps in implementing the strategy of moving from academia to industry and investing in assets based on innovation.
Camila McCabelli said ...
